TLSA Tiziana Life Sciences plc ADRs

Tiziana Life Sciences Plc, a clinical stage biotechnology company, focuses on the discovery and development of therapeutics to treat diseases in oncology and immunology in the United Kingdom. The company's product pipeline includes Milciclib (TZLS-201) that is in phase II clinical trials for epithelial thymic carcinoma and/or thymoma in patients previously treated with chemotherapy; and Foralumab (TZLS-401), a human anti-CD3 antibody, which completed phase IIa clinical trials for autoimmune and inflammatory diseases, such as non-alcoholic steatohepatitis, primary biliary cholangitis, ulcerative colitis, multiple sclerosis, autoimmune type-1 diabetes, inflammatory bowel diseases, and lupus. It also develops TZLS-501, a human anti IL-6R monoclonal antibody that is in pre-clinical development. The company was founded in 2013 and is headquartered in London, the United Kingdom. Tiziana Life Sciences Plc is a subsidiary of Planwise Group Limited. This is an ADR of a company whose stock trades outside of the U.S. as the symbol LN:TILS.

$0.74  -0.04 (-5.06%)
As of 10/03/2022 16:00:01 EST     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  ADRs
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  United Kingdom
Country of incorporation:  
IPO date:  11/20/2018
Outstanding shares:  102,272,614
Average volume:  95,780
Market cap:   $79,772,639
Current dividend yield:  0.00%
All SEC filings:   SEC Edgar Online
Annual filings:      20-F
Sedol:      
Valuation   (See tab for details)
PE ratio:   0.00
PB ratio:   3.15
PS ratio:   0.00
Return on equity:   -104.08%
Net income %:   0.00%

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy